
Challenging Bias: Making Diabetes Tech Accessible for Everyone
Within Range: Demystifying Diabetes Tech for Healthcare Professionals
Although guidelines are pointing to Automated Insulin Delivery Systems as standard of care for managing type 1 diabetes, not all people are being offered AID as a therapy option. Why are some people still left behind—and what can healthcare professionals do about it?
In this episode of Within Range from EASD 2025 in Vienna, host Kate Neal, Clinical Services Manager at Insulet, speaks with Dr. Alice Cheng and Dr. Hood Thabit about how unconscious bias, clinical inertia, and outdated assumptions continue to shape who gets offered diabetes technology.
They discuss what happens when healthcare teams assume patients “can’t handle” diabetes tech, how automation is breaking old barriers, and the practical strategies that make access fairer—from embedding technology conversations into every visit to using group starts and peer support to reach underrepresented communities.
Who you’ll hear from on this episode:
• Dr. Alice Cheng, endocrinologist at Trillium Health Partners, University of Toronto Associate Professor, and creator of the Med Ed Pledge, sharing how simple clinic routines can dismantle unconscious bias and make technology offers equitable.
• Dr. Hood Thabit, consultant diabetologist and Senior Lecturer at Manchester University NHS Foundation Trust, explaining how outreach, empathy, and inclusive education can bring marginalized groups into automated insulin delivery programs.
Disclaimer Note: The information in this podcast is accurate to the date of recording as of 09/18/2025. All HCPs interviewed received a fee from Insulet for taking part in this Podcast, views and opinions of these HCPs expressed in this podcast are their own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/engb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.
INS-OHS-11-2025-00168 v1.0